Navigation Links
Chemosensitivity of cancer cells depends on their protein dependency
Date:10/26/2009

Two different anti-apoptotic proteins support cancer cell survival via an identical mechanism, yet differ in their sensitivity to chemotherapeutic drugs, report Brunelle et al. The study will be published online October 26, 2009 and in the November 2, 2009 print issue of the Journal of Cell Biology (JCB).

Cancer cells often become dependent on one or more anti-apoptotic proteins to avoid death while continuing to proliferate. BCL-2, for example, is overexpressed in many cancers and mops up pro-apoptotic proteins to prevent them from permeabilizing mitochondria and initiating cell death. Other tumors are reliant on a related protein called MCL-1, but less is known about this member of the BCL-2 family. Brunelle et al. created leukemic mice overexpressing MCL-1 and compared them to similar mice that produced excess BCL-2.

The leukemias suffered by these two types of mice were identical, yet a technique called BH3 profiling was able to distinguish between cells derived from the different animals by demonstrating a dependency on one or other of the two anti-apoptotic proteins. Immunoprecipitation experiments revealed that MCL-1 and BCL-2 both work by sequestering the same two pro-apoptotic targets. Surprisingly then, leukemia cells reliant on MCL-1 were much more sensitive to a range of chemotherapeutic drugs than their BCL-2dependent counterparts were. Brunelle et al. found that the different cytotoxic drugs all caused a rapid decrease in MCL-1 protein levels via proteosome-mediated degradation, allowing cell death to proceed quickly. BCL-2 protein is more stable however, so additional time and more drug is needed to kill BCL-2dependent cancer cells.

Thus, the block in apoptosis selected during oncogenesis is not necessarily complete, and can have a major influence on the cancer's chemosensitivity. Senior author Anthony Letai now plans to use BH3 profiling on human tumors, to determine which anti-apoptotic protein a patient's cancer is dependent on and to correlate this with the tumor's response to chemotherapy.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert  

Related biology news :

1. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. ESF EURYI award winner aims to stop cancer cells reading their own DNA
4. Protein chatter linked to cancer activation
5. Newly created cancer stem cells could aid breast cancer research
6. Western diet linked to increased risk of colon cancer recurrence
7. Obesity and lack of exercise could enhance the risk of pancreatic cancer
8. Low levels of key protein may indicate pancreatic cancer risk
9. Birth records hold pancreatic cancer clue
10. Many parents at-risk for cancer disclose genetic test results to children
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemosensitivity of cancer cells depends on their protein dependency
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today ... clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place ... on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... DrugDev ... industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were on display ... 100 clinical trial leaders from over 40 sponsor, CRO and site organizations to discuss ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach USD ... the forecast period of 2016 to 2021 dominated by immunohistochemistry (IHC) ... largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... 225 pages, profiling 10 companies and supported with 181 tables and ...
Breaking Biology Technology: